Shots:
BMS has reported the 28wk. P-III (SCOUT-HCM) trial data assessing Camzyos (mavacamten) vs PBO in 44 pts (12 to <18yrs.) with symptomatic oHCM & NYHA class II-III symptoms, with plans to present 56wk. data in a future conference
Trial met its 1EP, showing reductions in Valsalva LVOT gradient at Wk. 28, supported by more pts…
